TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06605157

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AMUSED
Description: Delivered live by a board-certified music therapist (MT-BC) 40 min 2x/week for 12 weeks (24 total sessions; 16 total hours) in small groups of 3-5 people. A Multimodal mUSic therapy intervention for Engaging persons with severe Dementia (AMUSED) uses live participant-preferred music and progressively layers singing, touch, and rhythmic instrument playing concurrent with participant behavioral responses. Follows the Clinical Practice Model for Persons with Dementia and implementation strategies that promote cognition, attention, familiarity, audibility, structure, autonomy per participants' strengths, interests, preferences, culture, and momentary responses. Each small group works with the same music therapist throughout the study.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Reading Aloud
Description: Delivered live by a trained research assistant (interventionist) 40 min 2x/week for 12 weeks (24 total sessions; 16 total hours) in small groups of 3-5 people. The interventionist will read aloud from age-appropriate books (Chicken Soup for the Golden Soul by Jack Canfield; World of Wonders by Aimee Nezhukumatathil) selected to have sufficient material for all sessions, contain short stories to accommodate for attention span and session length, and offer choice. Follows implementation strategies identical to the music therapy arm (i.e., within the Clinical Practice Model for Persons with Dementia) that promote cognition, attention, familiarity, audibility, structure, autonomy per participants' strengths, interests, preferences, culture, and momentary responses. However, no music (including musical references) is used. Each small group works with the same reading interventionist throughout the study.
Study: NCT05029440

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulsed Electromagnetic Field
Description: PEMF was administered to the whole body for PEMF groups using a 1.8×0.6m mat 30 minutes/day, 3 times/week for 3 months.
Study: NCT06594757

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Toothbrushing with triple-headed manual toothbrush
Description: Toothbrushing with triple-headed manual toothbrush

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Toothbrushing with standard manual toothbrush
Description: Toothbrushing with tstandard manual toothbrush
Study: NCT06586515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3962673
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3962673
Description: Administered orally.
Study: NCT05029440

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Program
Description: The exercise training program included treadmill and aerobic exercises for hip and upper limb and performed for 50 minutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Program
Description: The exercise training program included treadmill and aerobic exercises for hip and upper limb and performed for 50 minutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Program
Description: The exercise training program included treadmill and aerobic exercises for hip and upper limb and performed for 50 minutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pulsed High Laser Therapy
Description: High Laser was delivered with a total dose of energy of 3000 J was delivered in two treatment phases. The initial phase was performed with fast manual scanning at 510, 610, and 710 mJ/cm2 in three successive subphases and 500 J in each subphase for a total of 1500 J. The final phase was the same as the initial phase except that the scanning was slow. The average area for the upper thigh or lower back was 200 cm2 with an average fluency of 15 J/cm2 and the application time for each area was 18 min. HILT was applied using a HIRO 3 device (ASA, Arcugnano, Vicenza, Italy).
Study: NCT06586515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: Administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin
Description: Administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: Administered intravenously.
Study: NCT06603077

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVTX-009 Regimen 1
Description: AVTX-009 will be administered as a subcutaneous injection every 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVTX-009 Regimen 2
Description: AVTX-009 will be administered as a subcutaneous injection every 2 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be administered as a subcutaneous injection every 2 weeks.
Study: NCT06139978

Intervention type: BEHAVIORAL
Intervention: ultrasound observation
Description: The relationship between the anteroposterior diameter of the CM and the gestational age and gender

Intervention type: BEHAVIORAL
Intervention: ultrasound observation
Description: The relationship between the anteroposterior diameter of the CM and the gestational age and gender
Study: NCT04646395

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafasitamab
Description: 200 mg powder for reconstitution with 5 ml water for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: 100 mg hard gelatin capsules
Study: NCT06147232

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotagliflozin
Description: Sodium-glucose-co-transporter 1 and 2 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotagliflozin
Description: Sodium-glucose-co-transporter 1 and 2 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablet
Study: NCT06664814

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ManNAc
Description: 2 grams twice daily by mouth
Study: NCT06666426

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PureWick System
Description: The PureWick System consists of the PureWick Urine Collection System used with the PureWick Flex Female External Catheter, which are intended for non-invasive urine output management.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hollister Female Urinary Pouch External Collection Device
Description: The Hollister Female Urinary Pouch External Collection Device is intended to collect and contain urine for individuals with urinary incontinence.
Study: NCT06668584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olutasidenib
Description: Given by mouth
Study: NCT05888532

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copper-64 labeled Granzyme B (64Cu-GRIP B)
Description: Given IV prior to imaging

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copper-64 labeled Granzyme B (64Cu-GRIP B)
Description: Given IV prior to imaging

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copper-64 labeled Granzyme B (64Cu-GRIP B)
Description: Given IV prior to imaging

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copper-64 labeled Granzyme B (64Cu-GRIP B)
Description: Given IV prior to imaging

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography (PET)
Description: Imaging procedure

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography (PET)
Description: Imaging procedure

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography (PET)
Description: Imaging procedure

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography (PET)
Description: Imaging procedure
Study: NCT06609239

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lunsekimig
Description: * Pharmaceutical form: Solution for injection in vial~* Route of administration: Subcutaneous injection
Study: NCT04782375

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stop group
Description: discontinue antiviral treatment
Study: NCT06661902

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buffered Lidocaine (1% Lidocaine + 8.4% Sodium Bicarbonate, in a 3:1 ratio)
Description: Given via injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Given via injection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biopsy of Prostate
Description: Undergo SOC prostate biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy of Prostate
Description: Undergo SOC prostate biopsy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT05143255

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: KNOW
Description: KNow the Optimal Way (KNOW) is a manualized ADRD patient-care partner intervention designed to increase engagement in advance care planning (ACP) and completion of advance directives among early stage ADRD patients and their care partners using theoretically grounded distress tolerance techniques (inhibitory learning theory) and communication skills (cognitive-social processing theory) consistent with recommended guidelines for discussions about ACP in ADRD care.
Study: NCT05706766

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PARE
Description: Aerobic and resistance exercise program via Zoom platform.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Waitlist Control Group
Description: Normal Activities.
Study: NCT06669247

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linvoseltamab
Description: Administered per protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN7945+Linvoseltamab
Description: Administered per protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN7945+Linvoseltamab
Description: Administered per protocol
Study: NCT05687266

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Datopotamab deruxtecan
Description: Intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle for up to 4 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle for up to 4 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle for a maximum of 35 cycles or 2 years (whichever occurs first).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle for up to 4 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle for up to 4 cycles.
Study: NCT05419050

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: denosumab
Description: monoclonal antibody to receptor activator of nuclear kappa-B ligand (RANKL), a protein involved in regulating osteoclastogenesis
Study: NCT06086886

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986454
Description: Specified dose on specified days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Specified dose on specified days
Study: NCT04843527

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FreeStyle Libre System
Description: FreeStyle Libre Flash Glucose Monitoring System

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FreeStyle Libre System plus food app
Description: FreeStyle Libre Flash Glucose Monitoring System and Smartphone Food Logging application
Study: NCT05834673

Intervention type: OTHER
Group type: OTHER
Intervention: SMS messages
Description: Participants will receive monthly SMS messages regarding cardiovascular health (low touch engagement nudges)

Intervention type: OTHER
Group type: OTHER
Intervention: Telephone-based support calls
Description: Participants will receive telephone-based support calls from a study nurse trained in motivational interviewing. These telephone calls will cover diet, exercise, medication, and where necessary smoking cessation. A summary of any recommendations will then be sent to the primary care physician via email or letter.

Intervention type: OTHER
Group type: OTHER
Intervention: GP Education
Description: Education of GPs on the European Society of Cardiology (ESC) guidelines and Guideline Directed Management Therapy

Intervention type: OTHER
Group type: OTHER
Intervention: GP Education
Description: Education of GPs on the European Society of Cardiology (ESC) guidelines and Guideline Directed Management Therapy
Study: NCT05367076

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-based Aerobic Exercise Program
Description: Community based FTTs will use a web-based platform to deliver a 12-week exercise training program (120-minute group sessions of aerobic activity 3 times/week). Each session will include:~* Warm-up activities~* Aerobic activities and fitness training in a game-like fashion~* Organized sports/games~* Cool down activity~* Snack/reward time
Study: NCT06611891

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-DOTATOC
Description: Slow direct intravenous injection
Study: NCT06611553

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of cervical sample by clinician

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cervical Biopsy
Description: Undergo cervical biopsy conducted by clinician

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colposcopy
Description: Undergo colposcopy conducted by clinician

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Health Record Review
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endocervical Curettage
Description: Undergo endocervical curettage conducted by clinician

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Excision
Description: Undergo cervical excisional procedure conducted by clinician

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HPV Self-Collection
Description: Undertake self-collection of vaginal sample

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Human Papillomavirus Test
Description: Undergo HPV testing of self-collected vaginal sample and cervical sample

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study: NCT05439200

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Asynchronous 3D movies
Description: 3D movies streamed at home for viewing on a handheld lenticular 3D screen

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Patching
Description: Adhesive patch to cover the fellow eye
Study: NCT05455294

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Navitoclax
Description: See Arm Description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Navitoclax
Description: See Arm Description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Navitoclax
Description: See Arm Description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Navitoclax
Description: See Arm Description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Navitoclax
Description: See Arm Description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: See Arm Description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: See Arm Description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: See Arm Description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: See Arm Description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: See Arm Description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: See Arm Description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: See Arm Description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: See Arm Description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: See Arm Description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: See Arm Description
Study: NCT05818462

Intervention type: DIAGNOSTIC_TEST
Intervention: Uroflow testing
Description: Uroflowmetry is a test that measures the volume of urine released from the body, the speed with which it is released, and how long the release takes.

Intervention type: DIAGNOSTIC_TEST
Intervention: Uroflow testing
Description: Uroflowmetry is a test that measures the volume of urine released from the body, the speed with which it is released, and how long the release takes.

Intervention type: DIAGNOSTIC_TEST
Intervention: Bladder Scan
Description: Bladder scan measures ultrasonic reflections within the patient's body to differentiate the urinary bladder from the surrounding tissue. In this case, it is used to detect the volume of urine in the bladder.

Intervention type: DIAGNOSTIC_TEST
Intervention: Bladder Scan
Description: Bladder scan measures ultrasonic reflections within the patient's body to differentiate the urinary bladder from the surrounding tissue. In this case, it is used to detect the volume of urine in the bladder.

Intervention type: OTHER
Intervention: Dysfunctional Voiding Scoring System Survey
Description: The Dysfunctional Voiding Symptom Score to provide accurate and objective numerical, grading of voiding behaviors of children.

Intervention type: OTHER
Intervention: Dysfunctional Voiding Scoring System Survey
Description: The Dysfunctional Voiding Symptom Score to provide accurate and objective numerical, grading of voiding behaviors of children.

Intervention type: DIAGNOSTIC_TEST
Intervention: DEXA Scan of pelvis and sacral spine
Description: DEXA (dual x-ray absorptiometry) scans measure bone density (thickness and strength of bones) by passing a high and low energy x-ray beam (a form of ionizing radiation) through the body, usually in the hip and the spine.

Intervention type: DIAGNOSTIC_TEST
Intervention: DEXA Scan of pelvis and sacral spine
Description: DEXA (dual x-ray absorptiometry) scans measure bone density (thickness and strength of bones) by passing a high and low energy x-ray beam (a form of ionizing radiation) through the body, usually in the hip and the spine.

Intervention type: DIAGNOSTIC_TEST
Intervention: Urine tests for specific biomarkers
Description: Urine tests for specific biomarkers (ATP, NGF, BNDF and urine proteomic screening).

Intervention type: DIAGNOSTIC_TEST
Intervention: Urine tests for specific biomarkers
Description: Urine tests for specific biomarkers (ATP, NGF, BNDF and urine proteomic screening).
Study: NCT06608901

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN7544
Description: Administered per the protocol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PB
Description: Administered per the protocol
Study: NCT06650475

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Using low or standart pressure
Description: Written consent will be obtained before the randomized study. Randomization will be done on the computer using a software program. Participants will be divided into two groups. Patients in Group S will undergo laparoscopy under standard pressures (12-16 mmHg) in laparoscopic surgery, while patients in Group L will undergo laparoscopy under low pressure (8-10 mm Hg).

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Using low or standart pressure
Description: Written consent will be obtained before the randomized study. Randomization will be done on the computer using a software program. Participants will be divided into two groups. Patients in Group S will undergo laparoscopy under standard pressures (12-16 mmHg) in laparoscopic surgery, while patients in Group L will undergo laparoscopy under low pressure (8-10 mm Hg).
Study: NCT06596473

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BG-C477
Description: Administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BG-C477
Description: Administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BG-C477
Description: Administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BG-C477
Description: Administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Administered in accordance with relevant local guidelines and/or prescribing information.
Study: NCT05566639

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1010
Description: Sterile liquid for injection
Study: NCT06590740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide-Formoterol treatment
Description: Budesonide 160 μg/formoterol 4.5 μg, 1 inhalation, BID
Study: NCT06667765

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RPT1G
Description: Dose formulation- Oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RPT1G
Description: Dose formulation- Oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Dose formulation- Oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Dose formulation- Oral capsule